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Abstract  
World Kidney Day 2016 focuses on kidney disease in childhood and the antecedents of adult 
kidney disease that can begin in earliest childhood.  Chronic kidney disease (CKD) in childhood 
differs from that in adults, as the largest diagnostic group among children includes congenital 
anomalies and inherited disorders, with glomerulopathies and kidney disease in the setting of 
diabetes being relatively uncommon.  In addition, many children with acute kidney injury will 
ultimately develop sequelae that may lead to hypertension and CKD in later childhood or in adult 
life. Children born early or who are small-for date newborns have relatively increased risk for the 
development of CKD later in life.  Persons with a high-risk birth and early childhood history 
should be watched closely in order to help detect early signs of kidney disease in time to provide 
effective prevention or treatment.  Successful therapy is feasible for advanced CKD in 
childhood; there is evidence that children fare better than adults, if they receive kidney 
replacement therapy including dialysis and transplantation, while only a minority of children 
may require this ultimate intervention Because there are disparities in access to care, effort is 
needed so that those children with kidney disease, wherever they live, may be treated effectively, 
irrespective of their geographic or economic circumstances.  Our hope is that World Kidney Day 
will inform the general public, policy makers and caregivers about the needs and possibilities 
surrounding kidney disease in childhood. 
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 “For in every adult there dwells the child 
that was, and in every child there lies the 
adult that will be.”  
― John Connolly, The Book of Lost Things 
 
Introduction and Overview   
The 11th World Kidney Day will be 
celebrated on March 10, 2016, around the 
globe.  This annual event, sponsored jointly 
by the International Society of Nephrology 
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(ISN) and the International Federation of 
Kidney Foundations (IFKF), has become a 
highly successful effort to inform the general 
public and policymakers about the 
importance and ramifications of kidney 
disease.  In 2016, World Kidney Day will be 
dedicated to kidney disease in childhood and 
the antecedents of adult kidney disease, 
which can begin in earliest childhood.   
Children who endure acute kidney injury 
(AKI) from a wide variety of conditions may 
have long-term sequelae that can lead to 
chronic kidney disease (CKD) many years 
later [1-4].  Further, CKD in childhood, 
much of it congenital, and complications 
from the many non-renal diseases that can 
affect the kidneys secondarily, not only lead 
to substantial morbidity and mortality during 
childhood but also result in medical issues 
beyond childhood.  Indeed, childhood deaths 
from a long list of communicable diseases 
are inextricably linked to kidney 
involvement.  For example, children who 
succumb to cholera and other diarrheal 
infections often die, not from the infection, 
but because of AKI induced by volume 
depletion and shock.  In addition, a 
substantial body of data indicates that 
hypertension, proteinuria and CKD in 
adulthood have childhood antecedents—
from as early as in utero and perinatal life 
[see Table 1 for definitions of childhood].  
 
Table 1. Definitions of Stages of Early Life 
Perinatal Period-   22 completed weeks of gestation to day 7 of postnatal life 
Neonatal Period-  Birth to day 28 of postnatal life 
Infancy Birth to 1 year of age 
Childhood 1 year of age to 10 years of age 
Adolescence 10 years of age to 19 years of age 
 
Notes: The data in this table are as defined by the 
World Health Organization. The perinatal period is 
defined as 22 completed weeks of gestation to Day 7 
of life; the neonatal period, as up to 28 days of life; 
infancy as up to one year of age; childhood as year 1 
to 10; and adolescence from 10 years to age 19. 
There is variation worldwide in how these stages of 
early life are defined.  Some would define “young 
people” as those ages 24 or less.  In the United 
States, childhood is as a whole defined as going to 
age 21. 
World Kidney Day 2016 aims to heighten 
general awareness that much adult renal 
disease is actually initiated in childhood.   
Understanding high risk diagnoses and 
events that occur in childhood have the 
potential to identify and intervene 
preemptively in those people at higher risk 
for CKD during their lifetimes. 
Worldwide epidemiologic data on the 
spectrum of both CKD and AKI in children 
are currently limited, though increasing in 
scope.  The prevalence of CKD in childhood 
is rare—and has been variously reported at 
15-74.7 per million children [3].  Such 
variation is likely because data on CKD are 
influenced by regional and cultural factors, 
as well as by the methodology used to 
generate them.  The World Health 
Organization (WHO) has recently added 
kidney and urologic disease to mortality 
information tracked worldwide, and should 
be a valuable source of such data over time 
— yet WHO does not post the information 
by age group [5].  Databases such as the 
North American Pediatric Renal Trials and 
Collaborative Studies (NAPRTCS) [6] the 
U.S. Renal Data System (USRDS) [7]  and 
the EDTA registry [8] include data on 
pediatric ESRD, and some on CKD. Projects 
such as the ItalKid [9] and Chronic Kidney 
Disease in Children (CKiD) [10] studies, the 
Global Burden of Disease Study 2013, as 
well as registries that now exist in many 
countries provide important information, and 
more is required [11].  
AKI may lead to CKD, according to selected 
adult population studies [12]. The incidence 
of AKI among children admitted to an 
intensive care unit varies widely—from 8% 
to 89% [1].   The outcome depends on the 
available resources. The results from 
projects such as the AWARE study, a five-
nation study of AKI in children are awaited 
[13].  Single center studies, as well as meta-
analyses indicate that both AKI and CKD in 
children account for a minority of CKD 
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worldwide [2,3].  However, it is increasingly 
evident that kidney disease in adulthood 
often springs from a childhood legacy. 
 
Spectrum of Pediatric Kidney Diseases 
 
The conditions that account for CKD in 
childhood, with a predominance of 
congenital and hereditary disorders, differ 
substantially from those in adults. To date, 
mutations in more than 150 genes have been 
found to alter kidney development or 
specific glomerular or tubular functions [14].  
Most of these genetic disorders present 
during childhood, and many lead to 
progressive CKD. Congenital anomalies of 
the kidney and urinary tract (CAKUT) 
account for the largest category of CKD in 
children [see Table 2] and include renal 
hypoplasia/dysplasia and obstructive 
uropathy.  
 
 The types and risks of kidney disease change across 
the lifecycle.   The contribution of nephron number 
increases over the life cycle, in concert with events 




Table 2.  Etiology of Chronic Kidney Disease 
in Children  
  
Rare causes include congenital NS, metabolic 
diseases, cystinosis/ 
Miscellaneous causes depend on how such entities 
are classified. 
CAKUT: Congenital anomalies of the kidney and 
urinary tract; GN: Glomerulonephritis; HN: 
Hereditary nephropathy; HUS: Hemolytic uremic 
syndrome 
*from Harambat et al.  CKD data are from 
NAPRTCS, the Italian Registry and the Belgian 
Registry.  ESRD data are from ANZDATA, 
ESPN/ERA-EDTA, UK Renal Registry and the 
Japanese Registry. 
 
Important subgroups among the renal 
dysplasias are the cystic kidney diseases, 
which originate from genetic defects of the 
tubuloepithelial cells’ primary cilia.  Many 
pediatric glomerulopathies are caused by 
genetic or acquired defects of the podocytes, 
the unique cell type lining the glomerular 
capillaries. Less common but important 
causes of childhood CKD are inherited 
metabolic disorders such as hyperoxaluria 
and cystinosis, and atypical hemolytic 
uremic syndrome, a thrombotic 
microangiopathy related to genetic 
abnormalities of complement, coagulation or 
metabolic pathways.  
In various classifications it is not clear how 
to categorize children who have suffered 
AKI and apparently recovered, or how and 
whether to include those children who have 
had perinatal challenges, likely resulting in a 
relatively low nephron number.  
Among children with childhood-onset end-
stage renal disease (ESRD) 
glomerulopathies are slightly more and 
congenital anomalies less common [Table 
2], due to the typically more rapid nephron 
loss in glomerular disease. However, recent 
evidence suggests that many patients with 
milder forms of CAKUT may progress to 
ESRD during adulthood, peaking in the 
fourth decade of life [15].  
There are national and regional differences 
in the types and course of both AKI and 
CKD during childhood and beyond.  Death 
from kidney disease is higher in developing 
nations, and national and regional disparities 
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in care and outcome must be addressed.  
Further, access to care is variable, depending 
on the region, the country and its 
infrastructure.   By focusing on kidney 
disease in childhood, cost-effective solutions 
may be reached, as treating disease early and 
preemptively may prevent later, more 
advanced CKD.  Expectations depend on the 
availability of care and management. 
Treating children, even from infancy, who 
have AKI and CKD that requires renal 
replacement therapy can be effective in 
mitigating the burden of kidney disease in 
adulthood.   Doing so requires resources that 
focus on the most expeditious and cost-
effective ways to deliver acute RRT in 
childhood. 
 
Congenital Kidney Disease and 
Developmental Origins of Health and 
Disease, Renal Endowment and 
Implications 
 
In regions where antenatal fetal ultrasounds 
are routine, many children with urologic 
abnormalities are identified antenatally, 
which permits early intervention. However, 
in much of the world, children with 
structural abnormalities are not identified 
until much later, when symptoms develop. 
While generalized screening for proteinuria, 
hematuria and urinary tract infections are 
carried out in some countries and regions, 
there is a lack of consensus as to its 
effectiveness.  However, there is general 
agreement that children with antenatal 
ultrasound studies that indicate possible 
genitourinary anomalies, children with a 
family history of kidney disease, and 
children with signs such as failure to thrive 
or a history of urinary tract infection, 
voiding dysfunction or  an abnormal 
appearing urine should be examined.  Initial 
screening would include a focused physical 
examination and a urine dipstick, formal 
urinalysis and a basic chemistry panel, 
followed by a more focused evaluation if 
indicated.   
Depending on the diagnosis, definitive 
therapy may be indicated.  However, the 
evidence that therapy will slow progression 
of CKD in childhood remains limited.  
Angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, antioxidants 
and, possibly, dietary changes may be 
indicated, depending on the diagnosis.  
However, dietary changes need to permit 
adequate growth and development.   The 
ESCAPE trial provided evidence that strict 
blood pressure control retards progression of 
CKD in children irrespective of the type of 
underlying kidney disease [16]. 
Some very young children may require renal 
replacement therapy in early infancy.  
Recent data pooled from registries 
worldwide indicate good survival, even 
when dialysis is required from neonatal age 
[2,17].  Kidney transplantation, the preferred 
renal replacement therapy in children, is 
generally suitable after 12 months of age, 
with excellent patient and allograft survival, 
growth and development.  
Evidence is accumulating that childhood-
onset CKD leads to accelerated 
cardiovascular morbidity and shortened life 
expectancy. Ongoing large prospective 
studies such as the (Cardiovascular 
Comorbidity in Children with CKD (4C) 
Study are expected to inform about the 
causes and consequences of early 
cardiovascular disease in children with CKD 
[18].  
In addition to those children with congenital 
kidney disease, it is now known that 
perinatal events may affect future health in 
the absence of evident kidney disease in 
early life [19].  Premature infants appear to 
be particularly at risk for kidney disease 
long after they are born, based both on 
observational cohort studies, as well as on 
case reports.  Increasingly premature infants 
survive, including many born well before 
nephrogenesis is complete [20]. The limited 
data available indicate that in the process of 
neonatal ICU care, such babies receive many 
nephrotoxins, and that those dying prior to 
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discharge from the nursery have fewer and 
larger glomeruli [21].  Additionally, those 
surviving have evidence of renal impairment 
that may be subtle [22].  Even more 
concerning, abundant epidemiologic data 
indicate that persons born at term but with 
relatively low birth weights may be at high 
risk for hypertension, albuminuria and CKD 
in later life [23].  When direct measurements 
are pursued, such persons, as adults, may 
have fewer nephrons, thus a low cardiorenal 
endowment.  
In focusing on children for World Kidney 
Day, we would note that it is key to follow 
kidney function and blood pressure 
throughout life in those persons born early 
or small-for-dates.  By doing so, and 
avoiding nephrotoxic medications 
throughout life, it may be possible to avert 
CKD in many people. 
 
Resources and Therapeutics for Children-
-Differences from Therapeutics in Adults.   
 
Disparities exist in the availability of 
resources to treat AKI in children and young 
people; consequently, too many children and 
young adults in developing nations succumb 
if AKI occurs.  To address the problem the 
ISN has initiated the Saving Young Lives 
Project, which aims both to prevent AKI 
with prompt treatment of infection and/or 
delivery of appropriate fluid and electrolyte 
therapy, and to treat AKI when it occurs.  
This ongoing project in SubSaharan Africa 
and South East Asia, in which four kidney 
foundations participate equally (IPNA, ISN, 
ISPD and SKCF),* focuses on establishing 
and maintaining centers for the care of AKI, 
including the provision of acute peritoneal 
dialysis.  It links with the ISN’s 0 by 25 
project, which calls on members to ensure 
by 2025 that nobody dies from preventable 
and acute kidney injury.    
In view of the preponderance of congenital 
and hereditary disorders, therapeutic 
resources for children with CKD have 
historically been limited to a few 
immunological conditions. Very recently, 
progress in drug development in concert 
with advances in genetic knowledge and 
diagnostic capabilities has begun to 
overcome the long-standing ‘therapeutic 
nihilism’ in pediatric kidney disease. 
Atypical HUS, long considered ominous,  
with a high likelihood of progression to 
ESRD and post-transplantation recurrence, 
has turned into a treatable condition - with 
the advent of a monoclonal antibody that 
specifically blocks C5 activation [24]. 
Another example is the use of vasopressin 
receptor antagonists to retard cyst growth 
and preserve kidney function in polycystic 
kidney disease [25]. First proven efficacious 
in adults with autosomal dominant 
polycystic kidney disease,  therapy with 
vaptans holds promise also for the recessive 
form of the disease, which presents and 
often  progresses to ESRD during childhood.  
However, patient benefit from 
pharmacological research breakthroughs is 
jeopardized on a global scale by the 
enormous cost of some of the new 
therapeutic agents. The quest for affordable 
innovative therapies for rare diseases will be 
a key issue in pediatric nephrology in the 
years to come.     
The identification of children likely to 
benefit from novel therapeutic approaches 
will be greatly facilitated by the 
development of clinical registries that 
inform about the natural disease course, 
including genotype-phenotype correlations. 
Apart from disease-specific databases, there 
is also a need for treatment-specific 
registries. These are particularly relevant in 
areas where clinical trials are difficult to 
perform due to small patient numbers and 
lacking industry interest, as well as for 
therapies in need of global development or 
improvement. For instance, there is currently 
a large international gradient in the 
penetration and performance of pediatric 
dialysis and transplantation. Whereas 
pediatric patient and technique survival rates 
are excellent and even superior to those of 
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adults in many industrialized countries, it is 
estimated that almost half of the world’s 
childhood population is not offered chronic 
renal replacement therapy (RRT) at all. 
Providing access to RRT for all children will 
be a tremendous future challenge. To obtain 
reliable information on the demographics 
and outcomes of pediatric RRT, the 
International Pediatric Nephrology 
Association (IPNA) is about to launch a 
global population-based registry. If 
successful, the IPNA RRT registry might 
become a role model for global data 
collection. 
 
Transition from Pediatric to Adult Care –  
 
Transition of care for adolescents with 
kidney disease into an adult setting is critical 
both for patients and their caregivers. Non-
adherence is a too-frequent hallmark of 
transition from pediatric to adult care for 
young patients with chronic disease states 
[26-28]. Hence, considered steps combined 
with systematically defined procedures 
supported by validated pathways and 
credible guidelines must be in place to 
ensure successful outcomes.  
In the process of change from pediatric to 
adult care “transition,” which should occur 
gradually, must be distinguished from 
“transfer,” which is often an abrupt and 
mechanistic change in provider setting.  
Introducing the concept of transition should 
be preemptive, starting months to years prior 
to the targeted time, as children move into 
adolescence and adulthood.  The ultimate 
goal is to foster a strong relationship and 
individualized plan in the new setting that 
allows the patient to feel comfortable 
enough to report non-adherence and other 
lapses in care.     
A transition plan must recognize that the 
emotional maturity of children with kidney 
disease may differ widely.  Assessment of 
the caregiver and the family structure as well 
as cultural, social, and financial factors at 
the time of transition are key, including a 
realistic assessment of caregiver burden [4]. 
The appropriate timing and format of 
transition may vary widely among different  
patients and in different settings; therefore, a 
flexible process without a set date and even 
without a delineated format may be 
preferred.   
Importantly, transition may need to be 
slowed, paused or even reversed temporarily 
during crises such as disease flares or 
progression, or if family or societal 
instability occurs.   A recent joint consensus 
statement by the International Society of 
Nephrology (ISN) and International 
Pediatric Nephrology Association (IPNA) 
proposed steps consistent with the points 
just outlined, aiming to enhance the 
transition of care in kidney disease in 
clinical practice [29,30].  
 
Call for Generating further Information 
and Action  
 
Given vulnerabilities of children with kidney 
disease including impact on growth and 
development and future life as an adult, and 
given the much greater proportion of 
children in developing nations facing 
resource constraints educating everyone 
involved is imperative in order  to realign 
communications and actions [31,32].  These 
efforts should foster regional and 
international collaborations and exchange of 
ideas between local kidney foundations, 
professional societies, other not-for-profit 
organizations, and states and governments, 
so as to help empower all stakeholders to 
improve the health, well-being and quality 
of life of children with kidney diseases and 
to ensure their longevity into adulthood. 
Until recently, however, the WHO 
consensus statement on non-communicable 
diseases (NCD) included cardiovascular 
disease, cancer, diabetes and chronic 
respiratory disease, but not kidney disease 
[33,34].   
Fortunately, due, in part, to a global 
campaign led by the ISN,  the Political 
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Declaration on NCDs from the United 
Nations Summit in 2011 mentioned kidney 
disease under Item 19 [35].  
Increasing education and awareness about 
renal diseases in general and kidney disease 
in childhood in particular is consistent with 
the objectives of the WHO to reduce 
mortality from NCD with a 10 year target 
population level initiatives focusing on 
changes in life style (including tobacco use 
reduction, salt intake control, dietary energy 
control, and alcohol intake reduction) and 
effective interventions (including blood 
pressure, cholesterol and glycemic control). 
Heightened efforts are needed to realign and 
expand these multidisciplinary 
collaborations with more effective focus on 
early detection and management of kidney 
disease in children. Whereas the issues 
related to kidney disease may be 
overshadowed by other NCDs with 
apparently larger public health implications 
such as diabetes, cancer, and cardiovascular 
diseases, our efforts should also increase 
education and awareness on such 
overlapping conditions as cardiorenal 
connections, the global nature of the CKD 
and ESRD as major NCDs, and the role of 
kidney disease as the multiplier disease and 
confounder for other NCDs.  White papers 
including consensus articles and blueprint 
reviews by world class experts can serve to 
enhance these goals [36].   
 
FOOTNOTE: (goes on Page 32) 
 
*The four partners are (in alphabetical 
order): IPNA (International Pediatric 
Nephrology Association), ISN (International 
Society of Nephrology), ISPD (International 
Society for Peritoneal Dialysis), SKCF 
(Sustainable Kidney Care Foundation). 
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